Cargando…
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
BACKGROUND: Approximately 60% of patients with chronic constipation (CC) have a significantly higher rate of loss of defecation desire (LODD). Bile acids are expected to have a restorative effect on defecation desire (DD) because they lower the rectal sensory threshold, which is an objective index o...
Autores principales: | Yamamoto, Atsushi, Kessoku, Takaomi, Tanaka, Kosuke, Takahashi, Kota, Kasai, Yuki, Ozaki, Anna, Iwaki, Michihiro, Kobayashi, Takashi, Yoshihara, Tsutomu, Misawa, Noboru, Ohkuma, Kanji, Fuyuki, Akiko, Higurashi, Takuma, Hosono, Kunihiro, Yoneda, Masato, Iwasaki, Tomoyuki, Kurihashi, Takeo, Nakatogawa, Machiko, Suzuki, Ayao, Taguri, Masataka, Oyamada, Shunsuke, Ariyoshi, Keisuke, Kobayashi, Noritoshi, Ichikawa, Yasushi, Nakajima, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260435/ https://www.ncbi.nlm.nih.gov/pubmed/35812817 http://dx.doi.org/10.1016/j.conctc.2022.100958 |
Ejemplares similares
-
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
por: Tanaka, Kosuke, et al.
Publicado: (2022) -
Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
por: Ozaki, Anna, et al.
Publicado: (2021) -
Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol
por: Yoshihara, Tsutomu, et al.
Publicado: (2022) -
Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care
por: Tanaka, Kosuke, et al.
Publicado: (2023) -
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)